ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

reproxalap

Also written as “Reproxalap Ophthalmic Solution (0.25%)”, “Reproxalap Ophthalmic Solution (0.5%)” and “ADX-102 Ophthalmic Solution (0.5%)”.

Its studies are mostly in Dry Eye Syndromes · Conjunctivitis, Allergic · Alopecia Areata · Uveitis, Anterior, led by 2 companies.

Drug pageReproxalap: every studyAll 20 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 3, since Apr 4, 201721 company-led studies, 1 open or runningNext primary completion: Nov 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Aldeyra Therapeutics200 open or runningphase 3since Apr 4, 2017Dec 14, 2016none ahead
Aldena Therapeuticsits history only11 open or runningphase 2since Jan 22, 2025Jan 22, 2025Nov 2026phase 2 · NCT06826196

Also a collaborator on its studies: ORA.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Aldeyra Therapeutics only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

Before these, 6 studies since Dec 14, 2016.

  1. Jun 9, 2018Named reproxalapINNProposed as its International Nonproprietary Name in WHO's List 119
  2. Aug 31, 2018Phase 2 study in Conjunctivitis, AllergicNCT03660878 · 52 enrolled · United States
  3. Oct 3, 2018Phase 2 study in Conjunctivitis, AllergicNCT03709121 · 70 enrolled · Canada
  4. Mar 15, 2019Phase 3 study in Dry Eye SyndromesNCT03879863 · 422 enrolled · United States
  5. Dec 19, 2019Phase 3 study in Conjunctivitis, AllergicNCT04207736 · 95 enrolled · Canada
  6. Dec 14, 2020Phase 3 study in Dry Eye SyndromesNCT04674358 · 329 enrolled · United States
  7. Jan 25, 2021Phase 3 study in Dry Eye SyndromesNCT04735393 · 757 enrolled · United States
  8. Jul 12, 2021Phase 2 study in Dry Eye SyndromesNCT04971031 · 158 enrolled · United States
  9. Sep 13, 2021Phase 3 study in Dry Eye SyndromesNCT05062330 · 361 enrolled · United States
  10. Oct 18, 2021Phase 2 study in Dry Eye SyndromesNCT05102409 · 56 enrolled · Canada
  11. Feb 1, 2022Phase 3 study in Conjunctivitis, AllergicNCT05234554 · 131 enrolled · Canada
  12. Jun 15, 2022Phase 2 study in Dry Eye SyndromesNCT05424549 · 63 enrolled · Canada
  13. Apr 25, 2024Phase 3 study in Dry Eye SyndromesNCT06389214 · 132 enrolled · Canada
  14. May 17, 2024Phase 3 study in Dry Eye SyndromesNCT06424444 · 421 enrolled · United States
  15. Jul 2, 2024Phase 3 study in Dry Eye SyndromesNCT06493604 · 116 enrolled · United States

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 20 Aldeyra Therapeutics leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06493604Dry Eye Syndromes · United States3CompletedFeb 27, 2025116
NCT06424444Dry Eye Syndromes · United States3CompletedNov 3, 2024421
NCT06389214Dry Eye Syndromes · Canada3CompletedJun 11, 2024132
NCT05424549Dry Eye Syndromes · Canada2CompletedMay 9, 202263
NCT05234554Conjunctivitis, Allergic · Canada3CompletedApr 22, 2023131
NCT05102409Dry Eye Syndromes · Canada2CompletedOct 25, 202156
NCT05062330Dry Eye Syndromes · United States3CompletedMar 4, 2022361
NCT04971031Dry Eye Syndromes · United States2CompletedSep 8, 2021158
NCT04735393Dry Eye Syndromes · United States3CompletedOct 11, 2022757
NCT04674358Dry Eye Syndromes · United States3CompletedSep 12, 2021329
NCT04207736Conjunctivitis, Allergic · Canada3CompletedFeb 16, 202195
NCT03879863Dry Eye Syndromes · United States3CompletedOct 4, 2019422
NCT03709121Conjunctivitis, Allergic · Canada2CompletedMar 20, 201970
NCT03660878Conjunctivitis, Allergic · United States2CompletedNov 19, 201952
NCT03494504Conjunctivitis, Allergic · United States3CompletedNov 5, 2018318
NCT03445650Sjogren-Larsson Syndrome · United States3CompletedJan 18, 202011
NCT03404115Dry Eye Syndromes · United States2CompletedJul 11, 2018300
NCT03162783Dry Eye Syndromes · United States2CompletedJul 6, 201751
NCT03131154Non-infectious Anterior Uveitis · United States3CompletedApr 19, 2019123
NCT03012165Conjunctivitis, Allergic · United States2CompletedMay 2017154

How it is read

Names in the registry

  • “Reproxalap Ophthalmic Solution (0.25%)”, 15 entries
  • “Reproxalap Ophthalmic Solution (0.5%)”, 3 entries
  • “ADX-102 Ophthalmic Solution (0.5%)”, 2 entries
  • “ALD-102 Solution”, 1 entry
  • “Reproxalap ophthalmic solution (0.25%)”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.